![PeerView Internal Medicine CME/CNE/CPE Video Podcast artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts113/v4/12/76/c1/1276c15a-f0d1-a417-0af0-133e31697033/mza_7702405001002816834.jpg/100x100bb.jpg)
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
PeerView Internal Medicine CME/CNE/CPE Video Podcast
English - July 06, 2022 23:00 - 53 minutes - ★★★★★ - 2 ratingsScience cme medical education cme credits peerview insession inreview internal medicine cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.